After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Yahoo Finance discussed the stock recently as it posted Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $6.72 and fluctuated between $6.90 as its day high and $6.34 as its day low. The current market capitalization of Avid Bioservices Inc is $424.97M. A total of 1.06 million shares were traded on the day, compared to an average of 1.44M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, CDMO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 56 BUYs and 39 SELLs from insiders. Insiders purchased 340,278 shares during that period but sold 181,698.
In the most recent transaction, Kwietniak Matthew R. sold 274 shares of CDMO for 6.77 per share on Jan 12. After the transaction, the Chief Commercial Officer now owns 19,829 company shares. In a previous transaction on Jan 10, Hart Daniel R sold 2,408 shares at 6.17 per share. CDMO shares that Chief Financial Officer owns now total 79,305.
Among the insiders who sold shares, Ziebell Mark R disposed of 1,346 shares on Jan 10 at a per-share price of $6.17. This resulted in the V. P., General Counsel holding 63,269 shares of CDMO after the transaction. In another insider transaction, Kwietniak Matthew R. sold 1,060 shares at $6.17 per share on Jan 10. Company shares held by the Chief Commercial Officer now total 19,434.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CDMO in the last 3 months, the mean price target is $13.00 with high estimates of $16.00 and low estimates of $7.00. In terms of 52-week highs and lows, CDMO has a high of $21.05 and a low of $4.07.
As of this writing, CDMO has an earnings estimate of $Avid Bioservices, Inc. per share for the current quarter. EPS was calculated based on a consensus of Cardio Diagnostics Holdings Inc estimates, with a high estimate of $NDMO per share and a lower estimate of $Societal CDMO, Inc.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CDMO’s latest balance sheet shows that the firm has $126.17M in Cash & Short Term Investments as of fiscal 2022. There were $182.53M in debt and $75.76M in liabilities at the time. Its Book Value Per Share was $2.90, while its Total Shareholder’s Equity was $174.53M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CDMO is Buy with a score of 4.40.
